<DOC>
	<DOCNO>NCT02850263</DOCNO>
	<brief_summary>Intravitreal aflibercept approve treatment visual impairment due diabetic macular oedema ( DMO ) Europe US August 2014 July 2014 respectively . The main objective observational cohort field study evaluate effectiveness intravitreal aflibercept describe follow-up well treatment pattern anti vascular endothelial growth factor ( anti-VEGF ) treatment na√Øve patient DMO routine clinical practice United Kingdom .</brief_summary>
	<brief_title>A Study Assess Effectiveness Aflibercept Routine Clinical Practice Patients With Diabetic Macular Oedema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients age 18 year old . Patients diagnose type 1 2 diabetes mellitus Patients diagnose DMO central involvement ( defined area centre subfield OCT ) treat intravitreal aflibercept ( accordance routine practice ) Patients decision initiate treatment intravitreal aflibercept make per investigator 's routine treatment practice prior study inclusion Patients must provide write informed consent Patients age 18 . Patients contraindication list SmPC intravitreal aflibercept . Patients preplanned cataract surgery observational period . Patients previously treat intravitreal antiVEGF within 28 day . Patients currently previously treat systemic antiVEGF . Patients previously treat intravitreal fluocinolone acetonide steroid . Patients participate investigational programme intervention outside routine clinical practice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Diabetic Macular Oedema</keyword>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Aflibercept</keyword>
</DOC>